Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTPRZ1 | P23471 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27224550 | 0.80 | — | — | |
| SCHEMBL11661367 | 0.78 | KDM4E (0.33) | KDM4E | |
| SCHEMBL5652848 | 0.75 | — | — | |
| SCHEMBL8155628 | 0.74 | MAOA (0.34) | MAPT | |
| Water SCHEMBL28356277 | 0.74 | ALDH1A1 (0.54) | KDM4EALDH1A1TDP1PTPRZ1PTPN1 | |
| SCHEMBL3550959 | 0.74 | — | — | |
| SCHEMBL900510 | 0.72 | KDM4E (0.41) | KDM4EALDH1A1TDP1PTPRZ1PTPN1 | |
| SCHEMBL10716988 | 0.72 | — | — | |
| SCHEMBL145124 | 0.72 | ALDH1A1 (0.52) | KDM4EALDH1A1TDP1PTPRZ1PTPN1 | |
| SCHEMBL28235092 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131260-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2023-04-27 | — | — | US | claimed |
| CN-114920757-A | Organic electroluminescent materials and devices | 北京夏禾科技有限公司 | 2022-08-19 | — | — | CN | claimed |
| US-11349080-B2 | Organic electroluminescent materials and devices | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2022-05-31 | — | — | US | claimed |
| CN-109912619-B | Organic electroluminescent materials and devices | 北京夏禾科技有限公司 | 2022-05-20 | — | — | CN | claimed |
| US-11274083-B2 | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | SYNGENTA CROP PROTECTION AG (CH) | 2022-03-15 | — | — | US | claimed |
| EP-3728237-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | claimed |
| EP-3728235-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | claimed |
| US-20210087151-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2021-03-25 | — | — | US | claimed |
| CN-109071506-B | Substituted 2- (hetero) arylimidazolyl carboxamides as pest control agents | 拜耳作物科学股份公司 | 2021-03-02 | — | — | CN | claimed |
| EP-3761791-A1 | USE OF HETEROARYL-TRIAZOLE AND HETEROARYL-TETRAZOLE COMPOUNDS AS PESTICIDES IN PLANT PROTECTION | Bayer Aktiengesellschaft (DE) | 2021-01-13 | — | — | EP | claimed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | claimed |
| EP-1351687-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| EP-1351688-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | claimed |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2003-01-16 | — | — | US | claimed |
| WO-2002047456-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | claimed |
| WO-2002047687-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | claimed |
| EP-1212302-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | claimed |
| WO-2001019796-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274083-B2 | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | UNG, TYMP, TYMS | KDM4E 1634/4885ALDH1A1 133/4885TDP1 207/4885 |
| US-20210087151-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | UNG, TYMP, TYMS | KDM4E 1634/4885ALDH1A1 133/4885TDP1 207/4885 |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, KDR, FFAR2 | KDM4E 1959/4885ALDH1A1 1801/4885TDP1 2921/4885 |
| US-20230131260-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | UNG, TYMP, TYMS | KDM4E 1497/4885ALDH1A1 170/4885TDP1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.